Tracy Gregory
Family · Dickson, TNNPI 1285977322
Payments from drug & device makers
Across 238 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$928
- AstraZeneca$456
- Lilly USA, LLC$361
- AbbVie$295
- Exact Sciences$271
- Amgen$223
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,53398%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $928 |
| AstraZeneca | 22 | $456 |
| Lilly USA, LLC | 20 | $361 |
| AbbVie | 19 | $295 |
| Exact Sciences | 10 | $271 |
| Amgen | 11 | $223 |
| Otsuka America Pharmaceutical, Inc. | 11 | $217 |
| Johnson & Johnson(2 entities) | 7 | $214 |
| Bayer | 10 | $212 |
| Pfizer | 8 | $136 |
| Nestle Healthcare Nutrition Inc. | 6 | $123 |
| Astellas Pharma US Inc | 2 | $120 |
| Sumitomo Pharma America, Inc. | 5 | $106 |
| GSK | 6 | $100 |
| Novartis | 6 | $95 |
| Esperion Therapeutics, Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Corcept Therapeutics | 2 | $61 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Boehringer Ingelheim | 3 | $54 |
| Amarin Pharma, Inc. | 3 | $53 |
| Dexcom, Inc. | 3 | $47 |
| Nevro Corp. | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Shield Therapeutics Inc | 2 | $33 |
| Merck | 2 | $30 |
| Alkermes, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Antares Pharma, Inc. | 1 | $20 |
| VBI Vaccine (delaware) Inc. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Medtronic | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $12 |
| Genentech USA, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,633 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 56 | $51,642 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $48,282 |
| OzempicSemaglutide | 27 | $45,866 |
| RybelsusSemaglutide | 27 | $43,016 |
| JardianceEmpagliflozin | 36 | $34,681 |
| JanumetSitagliptin Phos/Metformin Hcl | 44 | $34,355 |
| TradjentaLinagliptin | 36 | $32,672 |
| FarxigaDapagliflozin Propanediol | 31 | $24,150 |
| EliquisApixaban | 33 | $23,326 |
| LinzessLinaclotide | 26 | $19,256 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $15,265 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,813 |
| MyrbetriqMirabegron | 17 | $12,738 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $12,613 |
| GemtesaVibegron | 21 | $11,697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Janumet Xr | $30 | $98,609115 claims |
| Novo NordiskOzempic, Rybelsus | $928 | $88,88254 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $54 | $76,71484 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $100 | $63,54787 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $456 | $41,63869 claims |
| PfizerEliquis | $136 | $23,32633 claims |
| AbbVieLinzess | $295 | $19,25626 claims |
| Astellas Pharma US IncMyrbetriq | $120 | $12,73817 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $106 | $11,69721 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $2,693322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Dickson
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.